Publicaciones en colaboración con investigadores/as de Westmead Hospital (21)

2024

  1. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2022

  1. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

    Breast Cancer Research, Vol. 24, Núm. 1

  2. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

  2. Core Outcome Measures for Trials in People with Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery

    Critical Care Medicine, Vol. 49, Núm. 3, pp. 503-516

2020

  1. Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid)

    Frontiers in Medicine, Vol. 7

2019

  1. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243

  2. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2018

  1. Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

    European Urology

  2. Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2017

  1. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]

    European Urology, Vol. 72, Núm. 6, pp. 962-971

  2. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276

  3. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349

2015

  1. Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 1

2014

  1. Predictors and dynamics of postpartum relapses in women with multiple sclerosis

    Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 739-746

  2. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

    Annals of Neurology, Vol. 76, Núm. 6, pp. 880-890

2013

  1. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

    PLoS ONE, Vol. 8, Núm. 5

  2. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

    Brain, Vol. 136, Núm. 12, pp. 3609-3617